Holen Sie sich die Stockscreener-App
1.45
7.64%
-0.12
Vorhandelsmarkt:
1.47
0.02
+1.38%
Palisade Bio Inc Aktie (PALI) Neueste Nachrichten
Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn’s - Yahoo Finance
Palisade Bio, Inc. (PALI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Palisade backs away but others not ‘scarred’ of FSCD - BioWorld News
Palisade Bio at Stifel forum: pde4 bet advances into phase 2 - Investing.com Canada
Palisade Bio Gets Clearance for Phase 2 Trial of Ulcerative Colitis Treatment in Canada - Yahoo Finance
Palisade Bio receives Health Canada clearance for UC trial - Investing.com
Palisade Bio receives Health Canada clearance for UC trial By Investing.com - Investing.com Nigeria
Palisade Bio Announces Health Canada Clearance for Global Phase 2 ASCENTRA-UC Study of PALI-2108 in Ulcerative Colitis - Quiver Quantitative
Palisade Bio, Inc. Receives Health Canada CTA Clearance For ASCENTRA-UC Global Phase 2 Study Evaluating PALI-2108 - marketscreener.com
HC Wainwright & Co. reiterates Buy rating on Palisade Bio, $7 price target - TradingView
FDA clears Palisade Bio’s phase 2 trial for Crohn’s disease drug - Investing.com Nigeria
Palisade Bio Gets FDA Clearance for PALI-2108 in Crohn's Disease - Yahoo Finance
Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD - markets.businessinsider.com
FDA clears Palisade Bio’s phase 2 trial for Crohn’s disease drug By Investing.com - Investing.com South Africa
The FDA cleared Palisade Bio’s Crohn’s trial application. First patient dosing is targeted for early 2027. - Stock Titan
Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum - GlobeNewswire
Palisade Bio, Inc.(NasdaqCM: PALI) added to S&P Global BMI Index - marketscreener.com
Palisade Bio at H.C. Wainwright conference: IBD drug push By Investing.com - Investing.com Australia
Palisade Bio at H.C. Wainwright conference: IBD drug push - Investing.com
Palisade Bio at Morgan Stanley conference: broadens ibd push By Investing.com - Investing.com UK
Here's Why We're Not Too Worried About Palisade Bio's (NASDAQ:PALI) Cash Burn Situation - simplywall.st
Palisade Bio (PALI) Advances 5.26% as Shares Test Key Resistance at $2.31Regression Channel - siam.in
Palisade Bio to Participate in Upcoming Investor Conferences - GlobeNewswire
Three September healthcare conferences will include Palisade Bio management - Stock Titan
Palisade Bio (PALI) CEO reallocates 176K shares in gifts - Stock Titan
Palisade Bio Q3 EPS Decreased by Brookline Capital Markets - MarketBeat
Weekly Recap: Cash runway to Phase 2 readouts and Q2 loss, stock outlook - TradingView
FY2030 EPS Estimates for Palisade Bio Reduced by Analyst - MarketBeat
Palisade Bio (PALI) Edges Lower to $2.14 as Shares Test Narrow Trading RangeMFI Overbought - dars.gov.et
Palisade Bio (PALI): Commodore Capital group now reports 0.0% beneficial ownership - Stock Titan
Palisade Bio, Inc. (NASDAQ:PALI) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Palisade Bio (PALI): Soleus group reports 7.5% stake, 13.1M shares held - Stock Titan
HC Wainwright Has Weak Forecast for Palisade Bio Q3 Earnings - MarketBeat
Palisade Bio (PALI) Receives a Buy from Oppenheimer - The Globe and Mail
Oppenheimer Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $8 - Moomoo
H.C. Wainwright Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Palisade Bio Q2 loss widens to $10.6M as R&D costs surge for lead candidate - scanx.trade
Palisade Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Palisade Bio plans phase 2 ulcerative colitis trial in 2H 2026 - Investing.com Australia
Palisade Bio clears FDA for Phase 2 UC trial - scanx.trade
Palisade Bio (NASDAQ:PALI) Releases Quarterly Earnings Results, Hits Expectations - MarketBeat
Palisade Bio Reports Q2 2026 Results, Advances PALI-2108 Into Phase 2 Development for Ulcerative Colitis and Crohn’s Disease - Quiver Quantitative
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development - The Manila Times
Palisade Bio Q2 net loss widens on higher R&D costs - TradingView
Palisade Bio Reports Second Quarter 2026 Financial Results - GlobeNewswire
PALISADE BIO, INC. Q2 2026: Revenue $0.5M, EPS $(0.05) — 10-Q Summary - TradingView
Palisade Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Renaissance Technologies LLC Lowers Stake in Palisade Bio, Inc. $PALI - MarketBeat
Palisade Bio Inc (PALI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Palisade Bio Inc (PALI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Palisade Bio (PALI) Expected to Post Earnings on Monday - MarketBeat
PALI Q1 2026 Earnings: Deeper-than-Expected Loss of $0.05 per Share Drags Stock Down 3.32%High Estimate Range - dars.gov.et
BlackRock (PALI holder) discloses 6.0% ownership of Palisade Bio common stock - Stock Titan
Palisade Bio Inc (PALI) Risk Assessment: Volatility, Financial Risk & Investment Risk - tradingkey.com
Palisade Bio Inc (PALI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Palisade Bio Inc (PALI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Palisade Bio Inc (PALI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PALI|Palisade Bio Inc|Price:1.945|Chg%:+0.050 - TradingKey
Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2 - Yahoo Finance
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):